Basic principles of the pharmacokinetics of antisense oligonucleotide drugs

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 183-215

  Levin, Arthur A ^a   Yu, Rosie Z ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885566527     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Geary, R. S., Current assessment of PK/PD relationships for antisense therapeutics, World Congress of Pharmacy and Pharmaceutical Sciences, Nice, France, 2002.
2. Geary, R. S., Leeds, J. M., Fitchett, J., Burckin, T., Troung, L., Spainhour, C., Creek, M., and Levin, A. A., Pharmacokinetics and metabolism in mice of a phosphorothioate ASO antisense inhibitor of C-raf-1 kinase expression, Drug Metab. Dispos. 25 (11), 1272, 1997.
3. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A., Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate ODNs, Anticancer Drug Des. 12 (5), 383, 1997.
4. Geary, R. S., Leeds, J. M., Shanahan, W., Glover, J., Pribble, J., Truong, L., Fitchett, J., Burckin, R., Nicklin, P., Philips, J., and Levin, A. A., Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate ASOs: mouse to man, in American Association of Pharmaceutical Scientists, Pharm. Research, Plenum Press, Seattle, Washington, 1996, p. S.
5. Geary, R. S., Yu, R. Z., and Levin, A. A., Pharmacokinetics of phosphorothioate antisense ODNs, Curr. Opin. Invest. Drugs 2 (4), 562, 2001.
6. Glover, J. M., Leeds, J. M., Mant, T. G., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr., Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense ODN (ISIS 2302), J. Pharmacol. Exp. Ther. 282 (3), 1173, 1997.
7. Leeds, J. M., Henry, S. P., Geary, R. S., Burckin, T. A., and Levin, A. A., Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys, Antisense Nucl. Acid Drug Dev. 10 (6), 435, 2000.
8. Levin, A. A., A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides, Biochim. Biophys. Acta 1489 (1), 69, 1999.
9. Levin, A. A., Henry, S. P., Bennett, C. F., Cole, D. L., Hardee, G. E., and Srivatsa, G. S., Preclinical development of antisense therapeutics, in Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing, 1st ed., Oxender, D. L. and Post, L. E., eds., Springer-Verlag, Heidelberg, Germany, 1998, p. 131.
10. Levin, A. A., Geary, R. S., Leeds, J. M., Monteith, D. K., Yu, R. Z., Templin, M. V., and Henry, S. P., The pharmacokinetics and toxicity of phosphorothioate ASOs, in Biotechnology and Safety Assessment, 2nd ed., Thomas, J. A., ed., Taylor & Francis, Philadelphia, PA, 1998, p. 151.
11. Eckstein, F., Phosphorothioate ODNs: what is their origin and what is unique about them? Antisense Nucl. Acid Drug Dev. 10 (2), 117, 2000.
12. Slim, G. and Gait, M. J., Configurationally defined phosphorothioate-containing oligoribonucleotides in the study of the mechanism of cleavage of hammerhead ribozymes, Nucl. Acids Res. 19 (6), 1183, 1991.
13. Spitzer, S. and Eckstein, F., Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides, Nucl. Acids Res. 16 (24), 11691, 1988.
14. White, A. P., Reeves, K. K., Snyder, E., Farrell, J., Powell, J. W., Mohan, V., and Griffey, R. H., Hydration of single-stranded phosphodiester and phosphorothioate oligodeoxyribonucleotides, Nucl. Acids Res. 24 (16), 3261, 1996.
15. Koziolkiewicz, M., Krakoviak, A., Kwinkowski, M., Boczkowska, M., and Stec, W. J., Stereodifferntiation-the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H, Nucl. Acids Res. 23 (24), 5000, 1995.
16. Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., and Nerenberg, M. I., Effect of phosphorothioate modification of ODNs on specific protein binding, J. Biol. Chem. 269 (43), 26801, 1994.
17. Mou, T. C. and Gray, D. M., The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2′-O-methyl modifications, Nucl. Acids Res. 30 (3), 749, 2002.
18. Yu, D., Kandimalla, E. R., Roskey, A., Zhao, Q., Chen, L., Chen, J., and Agrawal, S., Stereo-enriched phosphorothioate ODNs: synthesis, biophysical and biological properties, Bioorg. Med. Chem. 8 (1), 275, 2000.
19. Teplova, M., Minasov, G., Tereshko, V., Inamati, G. B., Cook, P. D., Manoharan, M., and Egli, M., Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA, Nat. Struct. Biol. 6 (6), 535, 1999.
20. Geary, R. S., Ushiro-Watanabe, T., Truong, L., Freier, S. M., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., and Levin, A. A., Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified ASO analogs in rats, J. Pharmacol. Exp. Ther. 296 (3), 890, 2001.
21. Yu, R. Z., Geary, R. S., and Levin, A. A., Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides, Curr. Opin. Drug Discov. Dev. 7 (2), 195, 2004.
22. Sewell, L. K., Geary, R. S., Baker, B. F., Glover, J. M., Mant, T. G. K., Yu, R. Z., Tami, J. A., and Dorr, A. F., Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotides targeting tumor necrosis factor-alpha, J. Pharmacol. Exp. Ther. 303 (3), 1334, 2002.
23. Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R. S., and Nicklin, P. L., Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate ODN (CGP 69846A) after intravenous and subcutaneous administration, Biochem. Pharmacol. 54 (6), 657, 1997.
24. Templin, M. V., Levin, A. A., Graham, M. J., Aberg, P. M., Axelsson, B. I., Butler, M., Geary, R. S., and Bennett, C. F., Pharmacokinetic and toxicity profile of a phosphorothioate ASO following inhalation delivery to lung in mice, Antisense Nucl. Acid Drug Dev. 10 (5), 359, 2000.
25. Miner, P. B., Jr., Geary, R. S., Matson, J., Chuang, E., Xia, S., Baker, B. F., and Wedel, M. K., Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis, Ailment Pharmacol. Ther. 23 (10), 1427, 2006.
26. Geary, R. S., Teng, C. L., Truong, L., Perry, B., Sinko, P., and Hardee, G. E., First pass hepatic extraction of a partially modified chimeric antisense oligonucleotides in Beagle dogs, in Annual Meeting of the American Association of Pharmaceutical Scientists, Indianapolis, IN, 2000, p. 216.
27. Stavchansky, S., Geary, R. S., and Cho, M., Pharmacokinetics and hepatic first pass effect of an antisense oligonucleotide (ISIS 2302) in rats, in Annual Meeting of the American Association of Pharmaceutical Scientists, Indianapolis, IN, 2000, p. 216.
28. Geary, R. S., Yu, R. Z., Watanabe, T., Henry, S. P., Hardee, G. E., Chappell, A., Matson, J., Sasmor, H., Cummins, L., and Levin, A. A., Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotides: comparison across species, Drug Metab. Dispos. 31 (11), 1419, 2003.
29. Watanabe, T. A., Geary, R. S., and Levin, A. A., Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302), ASOs 16 (2), 169, 2006.
30. Bijsterbosch, M. K., Rump, E. T., De Vrueh, R. L., Dorland, R., van Veghel, R., Tivel, K. L., Biessen, E. A., van Berkel, T. J., and Manoharan, M., Modulation of plasma protein binding and in vitro liver cell uptake of phosphorothioate ODNs by cholesterol conjugation, Nucl. Acids Res. 28 (14), 2717, 2000.
31. Yu, R. Z., Geary, R. S., Leeds, J. M., Ushiro-Watanabe, T., Moore, M., Fitchett, J., Matson, J., Burckin, T., Templin, M. V., and Levin, A. A., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate ASO targeting human Ha-ras mRNA in mouse and monkey, J. Pharm. Sci. 90 (2), 182, 2001.
32. Leeds, J. M. and Geary, R. S., Pharmacokinetic properties of phosphorothioate ASOs in humans, in Antisense Research and Applications, 1st ed., Crooke, S. T., ed., Springer, Heidelberg, 1998, p. 217.
33. Nicklin, P. L., Craig, S. J., and Phillips, J. A., Pharmacokinetic properties of phosphorothioates in animals-absorption, distribution, metabolism and elimination, in Antisense Research and Applications, 1st ed., Crooke, S. T., ed., Springer, Berlin, 1998, p. 141.
34. Lorenz, P., Misteli, T., Baker, B. F., Bennett, C. F., and Spector, D. L., Nucleocytoplasmic shuttling: a novel in vitro property of antisense phosphorothioate ODNs, Nucl. Acids Res. 28 (2), 582, 2000.
35. Snyder, R. M., Mirabelli, C. K., and Crooke, S. T., Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions, Biochem. Pharmacol. 35 (6), 923, 1986.
36. Butler, M., Stecker, K., and Bennett, C. F., Cellular distribution of phosphorothioate ODNs in normal rodent tissues, Lab. Invest. 77 (4), 379, 1997.
37. Bijsterbosch, M. K., Manoharan, M., Rump, E. T., De Vrueh, R. L. A., van Veghel, R., Tival, K. L., Biessen, E. A. L., Bennett, F. C., Cook, D. P., and van Berkel, T. J. C., In vitro fate of phosphorothioate antisense ODNs: predominant uptake by scavenger receptors on endothelial cells, Nucl. Acids Res. 25 (16), 3290, 1997.
38. Butler, M., Crooke, R. M., Graham, M. J., Lemonidis, K. M., Lougheed, M., Murray, S. F., Witchell, D., Steinbrecher, U., and Bennett, C. F., Phosphorothioate ODNs distribute similarly in class A scavenger receptor knockout and wild-type mice, J. Pharmacol. Exp. Ther. 292 (2), 489, 2000.
39. Giacomini, K. M. and Sugiyama, Y., Membrane transporters and drug response, in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed., Brunton, L. L., ed., McGraw-Hill, New York, 2006, pp. 41.
40. Peng, B., Andrews, J., Nestorov, I., Brennan, B., Nicklin, P., and Rowland, M., Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate ASO ISIS 1082 in rat, Antisense Nucl. Acid Drug Dev. 11 (1), 15, 2001.
41. Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., Martin, M. J., and Crooke, R. M., In vitro distribution and metabolism of a phosphorothioate ASO within rat liver after intravenous administration, J. Pharmacol. Exp. Ther. 286 (1), 447, 1998.
42. Benimetskaya, L., Tonkinson, J. L., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W., and Stein, C. A., Binding of phosphorothioate ODNs to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin in P-chirality independent, Nucl. Acids Res. 23 (21), 4239, 1995.
43. Benimetskaya, L., Loike, J. D., Loike, G., Siverstein, S. C., Long, C., Khoury, J. E., Cai, T.-Q., and Stein, C. A., Mac-1 (CD11b/CD18) is an ODN-binding protein, Nat. Med. 3 (4), 414, 1997.
44. Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., and Neckers, L. M., Characterization of ASO transport into living cells, Proc. Natl. Acad. Sci. USA 86, 3474, 1989.
45. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A., Phosphorothioate ODNs bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix, J. Biol. Chem. 270, 2620, 1995.
46. Sawai, K., Mahato, R. I., Oka, Y., Takakura, Y., and Hashida, M., Disposition of ASOs in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake, J. Pharmacol. Exp. Ther. 279 (1), 284, 1996.
47. Levin, A. A., Henry, S. P., Monteith, D., and Templin, M., Toxicity of antisense oligonucleotides, in Antisense Drug Technology, Crooke, S. T., ed., Marcel Dekker, New York, 2001, p. 201.
48. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. T., Disposition of the 14C-labeled phosphorothioate ASO ISIS 2105 after intravenous administration to rats, J. Pharmacol. Exp. Ther. 267 (3), 1181, 1993.
49. 14C-labeled phosphorothioate ASO, ISIS 2105, after intradermal administration to rats, J. Pharmacol. Exp. Ther. 269 (1), 89, 1994.
50. Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., Greig, M. J., Guinosso, C. J., Kornbrust, D., Manoharan, M., Sasmor, H. M., Schleich, T., Tivel, K. L., and Griffey, R. H., Pharmacokinetic properties of several novel ASO analogs in mice, J. Pharmacol. Exp. Ther. 277 (2), 923, 1996.
51. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R., PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice, Proc. Natl. Acad. Sci. USA 99 (17), 1137, 2002.
52. Hua, X. Y., Moore, A., Malkmus, S., Murray, S. F., Dean, N., Yaksh, T. L., and Butler, M., Inhibition of spinal protein kinase C alpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance, Neuroscience 113 (1), 99, 2002.
53. Butler, M., Hayes, C. S., Chappell, A., Murray, S. F., Yaksh, T. L., and Hua, X. Y., Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified ASOs after intrathecal administration in rats, Neuroscience 131 (3), 705, 2005.
54. Driver, S. E., Robinson, G. S., Flanagan, J., Shen, W., Smith, L. E. H., Thomas, D. W., and Roberts, P. C., ASO-based inhibition of embryonic gene expression, Nat. Biotechnol. 17, 1184, 1999.
55. Soucy, N. V., Riley, J. P., Templin, M. V., Geary, R., de Peyster, A., and Levin, A. A., Maternal and fetal distribution of a phosphorothioate ASO in rats after intravenous infusion, Birth Defects Res. B Dev. Reprod. Toxicol. 77 (1), 22, 2006.
56. Henry, S. P., Denny, K. H., Templin, M. V., Yu, R. Z., and Levin, A. A., Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice, Birth Defects Res. B Dev. Reprod. Toxicol. 71 (6), 359, 2004.
57. Yu, R. Z., Zhang, H., Geary, R. S., Graham, M., Masarjian, L., Lemonidis, K., Crooke, R., Dean, N. M., and Levin, A. A., Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate ASO targeting Fas mRNA in mice, J. Pharmacol. Exp. Ther. 296 (2), 388, 2001.
58. Wilson, D. M., 3rd, Ape1 abasic endonuclease activity is regulated by magnesium and potassium concentrations and is robust on alternative DNA structures, J. Mol. Biol. 345 (5), 1003, 2005.
59. Gaus, H. J., Owens, S. R., Winniman, M., Cooper, S., and Cummins, L. L., On-line HPLC electrospray mass spectrometry of phosphorothioate ASO metabolites, Anal. Chem. 69 (3), 313, 1997.
60. Yu, R. Z., Baer, B., Chappel, A., Geary, R. S., Chueng, E., and Levin, A. A., Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate ODN in plasma, Anal. Biochem. 304 (1), 19, 2002.
61. Jackson, J. K., Gleave, M. E., Gleave, J., and Burt, H. M., The inhibition of angiogenesis by antisense oligonucleotides to clusterin, Angiogenesis 8 (3), 229, 2005.
62. Gleave, M. and Chi, K. N., Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers, Ann. NY Acad. Sci. 1058, 1, 2005.
63. Gleave, M. and Miyake, H., Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen-and chemo-sensitivity in prostate cancer, World J. Urol. 23 (1), 38, 2005.
64. Adjei, A. A., Dy, G. K., Erlichman, C., Reid, J. M., Sloan, J. A., Pitot, H. C., Alberts, S. R., Goldberg, R. M., Hanson, L. J., Atherton, P. J., Watanabe, T., Geary, R. S., Holmlund, J., and Dorr, F. A., A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer, Clin. Cancer Res. 9 (1), 115, 2003.
65. Villalona-Calero, M. A., Ritch, P., Figueroa, J. A., Otterson, G. A., Belt, R., Dow, E., George, S., Leonardo, J., McCachren, S., Miller, G. L., Modiano, M., Valdivieso, M., Geary, R. S., Oliver, J. W., and Holmlund, J., A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer, Clin. Cancer Res. 10 (18 Pt 1), 6086, 2004.
66. Geary, R. S., Bradley, J. D., Watanabe, T., Kwon, Y., Wedel, M., van Lier, J. J., and Vanvliet, A. A., Lack of pharmacokinetic interaction for ISIS 113715, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone, Clin. Pharmacokinet. 45 (8), 789, 2006.
67. Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. O., Yu, R. Z., Chuang, E., Graham, M. J., and Crooke, R. M. Potent reduction of apolipoprotein B and Low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114 (16), 1729, 2006.
68. Yu. R. Z., Kim, T. W., Hong, A., Watanabe, T. A., Gaus, H. J., and Geary, R. S. Cross species, Pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apolipoprotein 8-100. Drug Metab. Dispos. 35, 460, 2007.